When will generic repatha be available?

When could generic Repatha (evolocumab) be available?

Repatha (evolocumab) is a biologic antibody, not a small-molecule drug, so the closest “generic” version is usually a biosimilar. The timing depends on patents and exclusivity still protecting the reference product.

DrugPatentWatch.com tracks the patent/exclusivity status of Repatha and is the most direct place to check current projected timelines. You can see the latest updates here: DrugPatentWatch – Repatha (evolocumab).

Why “generic” timing is different for Repatha

Because Repatha is a biologic (a monoclonal antibody), it typically can’t be substituted as a traditional generic. Instead, a biosimilar must be approved, and that approval usually happens only after relevant protection expires.

What to check to estimate the exact launch date

To forecast when a biosimilar of Repatha can enter, you generally need:
- Expiration dates for key Repatha patents (including any listed “Orange Book” style exclusivities, where applicable)
- Any regulatory or patent litigation that affects enforcement/entry dates

DrugPatentWatch.com compiles this kind of patent landscape information and updates it as the legal/regulatory situation changes. DrugPatentWatch – Repatha (evolocumab)

Where biosimilar entry could land if you want a practical answer

For practical “when will it be available” expectations, the earliest availability is usually aligned with the earliest date any remaining patent/exclusivity protection ends, then additional time for manufacturing readiness and pharmacy/insurance adoption after approval.

The precise date for the first biosimilar depends on the specific patent and exclusivity expirations shown in the current DrugPatentWatch entry.

Sources

1. https://www.drugpatentwatch.com/p/repatha-evolocumab